Theravance Biopharma, Inc. announced enrollment of the first patient in a Phase 4 study of YUPELRI®(revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Success in this study is intended to capture more of YUPELRI's addressable market and further strengthen its competitive advantage.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.89 USD | -1.00% | +12.13% | -12.01% |
06-24 | Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index | CI |
05-23 | Transcript : Theravance Biopharma, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.01% | 481M | |
+55.35% | 815B | |
+31.67% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.09% | 247B | |
+14.23% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study